Myqorzo

(Aficamten)

Phase 3Small molecule

Myqorzo is a small molecule that works as a Cardiac Myosin Inhibitor.[2] It is being investigated across 3 indications, with its most advanced program in Phase 3.[1]

Myqorzo is one of 36 small molecule programs targeting Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Patents

Pipeline

Status by Indication[3][1]

Indication

Symptomatic Non-Obstructive Hypertrophic CardiomyopathyActive, not recruiting

Symptomatic Obstructive Hypertrophic CardiomyopathyActive, not recruiting

AdultEnrolling by invitation

Symptomatic Non-Obstructive Hypertrophic CardiomyopathyPhase 3

Active, not recruiting

Symptomatic Obstructive Hypertrophic CardiomyopathyPreclinical

Active, not recruiting

AdultPhase 3

Enrolling by invitation

Competition

Competitive Landscape

127 competitors in Adult

#DrugCompanyPhaseTrials

Nydrazid

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

1 2

Tebrazid

AAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

Phase 3

1 3

Mounjaro

Eli Lilly

Phase 2

1 4

Rifampicin

Boehringer Ingelheim

Phase 3

3 5

Myqorzo

CCytokinetics

Phase 3

1 6

Opzelura

DDizal Pharmaceuticals

Phase 2

1 7

NM8074

NNovelMed Therapeutics

Phase 2

2 8

EB-1020

Otsuka

Phase 3

1 9

Augtyro

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 1

1 10

Ansaid

PPharmacia and Upjohn

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 3Active, not recruiting

Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy

NCT06081894

Q1 2030

PreclinicalActive, not recruiting

Symptomatic Obstructive Hypertrophic Cardiomyopathy

NCT06412666

Clinical

Trials by Indication[1]

Efficacy and Safety2 trials

Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults With Symptomatic oHCM

Completed·CCytokinetics·Phase 3·NCT05767346·175 enrolled

Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic oHCM

Completed·CCytokinetics·Phase 3·NCT05186818·282 enrolled

Adult1 trial

Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten in Adults With HCM

Enrolling by invitation·CCytokinetics·Phase 2/3·NCT04848506·900 enrolled

Symptomatic Obstructive Hypertrophic Cardiomyopathy1 trial

A Phase 2/3 Multicenter, Randomized, Double-Blind, Placebo-Controlled and Open-Label Extension Trial to Evaluate the Efficacy and Safety of Aficamten in a Pediatric Population With Symptomatic Obstructive Hypertrophic Cardiomyopathy

Active, not recruiting·CCytokinetics·Preclinical·NCT06412666·65 enrolled

Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy1 trial

A Phase 3, Multi-Center, Randomized, Double-Blind Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy

Active, not recruiting·CCytokinetics·Phase 3·NCT06081894·500 enrolled

Unspecified2 trials

An Open-Label Study of Aficamten for Chinese Patients With Symptomatic oHCM

Completed·CCorxel Pharmaceuticals·Phase 3·NCT06116968·40 enrolled

Study to Evaluate the Effect of Aficamten Administration on QT/QTc Interval

Completed·CCytokinetics·Phase 1·NCT05924815·44 enrolled

Regulatory

FDA Approval Timeline[4]

Dec 19, 2025

MYQORZO

NDA NDA219083

Dec 19, 2025

MYQORZO

NDA NDA219083

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for Aficamten. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Aficamten compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Aficamten. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA219083). U.S. Food & Drug Administration.
[5]
FDA Orange Book — Patent and exclusivity data for Myqorzo. U.S. Food & Drug Administration.
[6]
PubMed — 1 publication indexed for Aficamten. U.S. National Library of Medicine.
[7]
SEC EDGAR — Cytokinetics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Cardiac Myosin Inhibitor[2]
Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: CCytokinetics

Patent Landscape[5]

Patent Cliff

Jan 18, 2039

Earliest patent expiration — generic entry possible after this date

Patent #Expires

10836755Jan 18, 2039

12370179Jul 15, 2042

Key Publications[6]

Aficamten in Obstructive HCM: SEQUOIA-HCM Phase 3

N Engl J MedAug 31, 2024DOI: 10.1056/NEJMoa2408752

Myqorzo

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2030

Trials by Indication[1]

Efficacy and Safety2 trials

Adult1 trial

Symptomatic Obstructive Hypertrophic Cardiomyopathy1 trial

Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy1 trial

Unspecified2 trials

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Patent Landscape[5]

Key Publications[6]

Related News